Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of TLL-018 ER vs IR in Healthy Chinese Subjects
NCT05945810Phase 1Completed
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd.
- Start
- Jul 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of girocitinib in atopic dermatitis (AD) (2 arms), sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Time t at Day 11, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity at Day 11 and 1 more. Started Jul 2023; status: completed.
02
Drugs
girocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05945810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05945810.